Large Molecule Bioanalytical Testing Service Market Size, Share, Growth, Trends, Company Analysis, Regional Insights and Forecast 2020 - 2027

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Large Molecule Bioanalytical Testing Service Market, By Phase Type

7.1.  Large Molecule Bioanalytical Testing Service Market, By Phase Type, 2020-2030

7.1.1.    Preclinical

7.1.1.1.        Market Revenue and Forecast (2016-2030)

7.1.2.    With Antibody

7.1.2.1.        Market Revenue and Forecast (2016-2030)

7.1.3.    Without Antibody (ELISA Based Assay)

7.1.3.1.        Market Revenue and Forecast (2016-2030)

7.1.4.    Clinical

7.1.4.1.        Market Revenue and Forecast (2016-2030)

Chapter 8.  Global Large Molecule Bioanalytical Testing Service Market, By Type

8.1.  Large Molecule Bioanalytical Testing Service Market, By Type, 2020-2030

8.1.1.    Pharmacokinetics

8.1.1.1.        Market Revenue and Forecast (2016-2030)

8.1.2.    ADA

8.1.2.1.        Market Revenue and Forecast (2016-2030)

8.1.3.    Others

8.1.3.1.        Market Revenue and Forecast (2016-2030)

Chapter 9.  Global Large Molecule Bioanalytical Testing Service Market, By Test Type

9.1.  Large Molecule Bioanalytical Testing Service Market, By Test Type, 2020-2030

9.1.1.    ADME

9.1.1.1.        Market Revenue and Forecast (2016-2030)

9.1.2.    PK

9.1.2.1.        Market Revenue and Forecast (2016-2030)

9.1.3.    PD

9.1.3.1.        Market Revenue and Forecast (2016-2030)

9.1.4.    Bioavailability

9.1.4.1.        Market Revenue and Forecast (2016-2030)

9.1.5.    Bioequivalence

9.1.5.1.        Market Revenue and Forecast (2016-2030)

9.1.6.    Other Tests

9.1.6.1.        Market Revenue and Forecast (2016-2030)

Chapter 10.      Global Large Molecule Bioanalytical Testing Service Market, By Therapeutic Area

10.1.        Large Molecule Bioanalytical Testing Service Market, By Therapeutic Area, 2020-2030

10.1.1.  Oncology

10.1.1.1.      Market Revenue and Forecast (2016-2030)

10.1.2.  Infectious Diseases

10.1.2.1.      Market Revenue and Forecast (2016-2030)

10.1.3.  Cardiology

10.1.3.1.      Market Revenue and Forecast (2016-2030)

10.1.4.  Neurology

10.1.4.1.      Market Revenue and Forecast (2016-2030)

Chapter 11.      Global Large Molecule Bioanalytical Testing Service Market, By End-user Type

11.1.        Large Molecule Bioanalytical Testing Service Market, By End-user, 2020-2030

11.1.1.  SMEs

11.1.1.1.      Market Revenue and Forecast (2016-2030)

11.1.2.  Large Firms

11.1.2.1.      Market Revenue and Forecast (2016-2030)

Chapter 12.      Global Large Molecule Bioanalytical Testing Service  Market, Regional Estimates and Trend Forecast

12.1.        North America

12.1.1.  Market Revenue and Forecast, By Phase (2016-2030)

12.1.2.  Market Revenue and Forecast, By Type (2016-2030)

12.1.3.  Market Revenue and Forecast, By Test (2016-2030)

12.1.4.  Market Revenue and Forecast, By Therapeutic Area (2016-2030)

12.1.5.  Market Revenue and Forecast, By End-user (2016-2030)

12.1.6.  U.S.

12.1.6.1.      Market Revenue and Forecast, By Phase (2016-2030)

12.1.6.2.      Market Revenue and Forecast, By Type (2016-2030)

12.1.6.3.      Market Revenue and Forecast, By Test (2016-2030)

12.1.6.4.      Market Revenue and Forecast, By Therapeutic Area (2016-2030)

12.1.7.  Market Revenue and Forecast, By End-user (2016-2030)

12.1.8.  Rest of North America

12.1.8.1.      Market Revenue and Forecast, By Phase (2016-2030)

12.1.8.2.      Market Revenue and Forecast, By Type (2016-2030)

12.1.8.3.      Market Revenue and Forecast, By Test (2016-2030)

12.1.8.4.      Market Revenue and Forecast, By Therapeutic Area (2016-2030)

12.1.8.5.      Market Revenue and Forecast, By End-user (2016-2030)

12.2.        Europe

12.2.1.  Market Revenue and Forecast, By Phase (2016-2030)

12.2.2.  Market Revenue and Forecast, By Type (2016-2030)

12.2.3.  Market Revenue and Forecast, By Test (2016-2030)

12.2.4.  Market Revenue and Forecast, By Therapeutic Area (2016-2030)

12.2.5.  Market Revenue and Forecast, By End-user (2016-2030)

12.2.6.  UK

12.2.6.1.      Market Revenue and Forecast, By Phase (2016-2030)

12.2.6.2.      Market Revenue and Forecast, By Type (2016-2030)

12.2.6.3.      Market Revenue and Forecast, By Test (2016-2030)

12.2.7.  Market Revenue and Forecast, By Therapeutic Area (2016-2030)

12.2.8.  Market Revenue and Forecast, By End-user (2016-2030)

12.2.9.  Germany

12.2.9.1.      Market Revenue and Forecast, By Phase (2016-2030)

12.2.9.2.      Market Revenue and Forecast, By Type (2016-2030)

12.2.9.3.      Market Revenue and Forecast, By Test (2016-2030)

12.2.10.               Market Revenue and Forecast, By Therapeutic Area (2016-2030)

12.2.11.               Market Revenue and Forecast, By End-user (2016-2030)

12.2.12.               France

12.2.12.1.   Market Revenue and Forecast, By Phase (2016-2030)

12.2.12.2.   Market Revenue and Forecast, By Type (2016-2030)

12.2.12.3.   Market Revenue and Forecast, By Test (2016-2030)

12.2.12.4.   Market Revenue and Forecast, By Therapeutic Area (2016-2030)

12.2.13.               Market Revenue and Forecast, By End-user (2016-2030)

12.2.14.               Rest of Europe

12.2.14.1.   Market Revenue and Forecast, By Phase (2016-2030)

12.2.14.2.   Market Revenue and Forecast, By Type (2016-2030)

12.2.14.3.   Market Revenue and Forecast, By Test (2016-2030)

12.2.14.4.   Market Revenue and Forecast, By Therapeutic Area (2016-2030)

12.2.15.               Market Revenue and Forecast, By End-user (2016-2030)

12.3.        APAC

12.3.1.  Market Revenue and Forecast, By Phase (2016-2030)

12.3.2.  Market Revenue and Forecast, By Type (2016-2030)

12.3.3.  Market Revenue and Forecast, By Test (2016-2030)

12.3.4.  Market Revenue and Forecast, By Therapeutic Area (2016-2030)

12.3.5.  Market Revenue and Forecast, By End-user (2016-2030)

12.3.6.  India

12.3.6.1.      Market Revenue and Forecast, By Phase (2016-2030)

12.3.6.2.      Market Revenue and Forecast, By Type (2016-2030)

12.3.6.3.      Market Revenue and Forecast, By Test (2016-2030)

12.3.6.4.      Market Revenue and Forecast, By Therapeutic Area (2016-2030)

12.3.7.  Market Revenue and Forecast, By End-user (2016-2030)

12.3.8.  China

12.3.8.1.      Market Revenue and Forecast, By Phase (2016-2030)

12.3.8.2.      Market Revenue and Forecast, By Type (2016-2030)

12.3.8.3.      Market Revenue and Forecast, By Test (2016-2030)

12.3.8.4.      Market Revenue and Forecast, By Therapeutic Area (2016-2030)

12.3.9.  Market Revenue and Forecast, By End-user (2016-2030)

12.3.10.               Japan

12.3.10.1.   Market Revenue and Forecast, By Phase (2016-2030)

12.3.10.2.   Market Revenue and Forecast, By Type (2016-2030)

12.3.10.3.   Market Revenue and Forecast, By Test (2016-2030)

12.3.10.4.   Market Revenue and Forecast, By Therapeutic Area (2016-2030)

12.3.10.5.   Market Revenue and Forecast, By End-user (2016-2030)

12.3.11.               Rest of APAC

12.3.11.1.   Market Revenue and Forecast, By Phase (2016-2030)

12.3.11.2.   Market Revenue and Forecast, By Type (2016-2030)

12.3.11.3.   Market Revenue and Forecast, By Test (2016-2030)

12.3.11.4.   Market Revenue and Forecast, By Therapeutic Area (2016-2030)

12.3.11.5.   Market Revenue and Forecast, By End-user (2016-2030)

12.4.        MEA

12.4.1.  Market Revenue and Forecast, By Phase (2016-2030)

12.4.2.  Market Revenue and Forecast, By Type (2016-2030)

12.4.3.  Market Revenue and Forecast, By Test (2016-2030)

12.4.4.  Market Revenue and Forecast, By Therapeutic Area (2016-2030)

12.4.5.  Market Revenue and Forecast, By End-user (2016-2030)

12.4.6.  GCC

12.4.6.1.      Market Revenue and Forecast, By Phase (2016-2030)

12.4.6.2.      Market Revenue and Forecast, By Type (2016-2030)

12.4.6.3.      Market Revenue and Forecast, By Test (2016-2030)

12.4.6.4.      Market Revenue and Forecast, By Therapeutic Area (2016-2030)

12.4.7.  Market Revenue and Forecast, By End-user (2016-2030)

12.4.8.  North Africa

12.4.8.1.      Market Revenue and Forecast, By Phase (2016-2030)

12.4.8.2.      Market Revenue and Forecast, By Type (2016-2030)

12.4.8.3.      Market Revenue and Forecast, By Test (2016-2030)

12.4.8.4.      Market Revenue and Forecast, By Therapeutic Area (2016-2030)

12.4.9.  Market Revenue and Forecast, By End-user (2016-2030)

12.4.10.               South Africa

12.4.10.1.   Market Revenue and Forecast, By Phase (2016-2030)

12.4.10.2.   Market Revenue and Forecast, By Type (2016-2030)

12.4.10.3.   Market Revenue and Forecast, By Test (2016-2030)

12.4.10.4.   Market Revenue and Forecast, By Therapeutic Area (2016-2030)

12.4.10.5.   Market Revenue and Forecast, By End-user (2016-2030)

12.4.11.               Rest of MEA

12.4.11.1.   Market Revenue and Forecast, By Phase (2016-2030)

12.4.11.2.   Market Revenue and Forecast, By Type (2016-2030)

12.4.11.3.   Market Revenue and Forecast, By Test (2016-2030)

12.4.11.4.   Market Revenue and Forecast, By Therapeutic Area (2016-2030)

12.4.11.5.   Market Revenue and Forecast, By End-user (2016-2030)

12.5.        Latin America

12.5.1.  Market Revenue and Forecast, By Phase (2016-2030)

12.5.2.  Market Revenue and Forecast, By Type (2016-2030)

12.5.3.  Market Revenue and Forecast, By Test (2016-2030)

12.5.4.  Market Revenue and Forecast, By Therapeutic Area (2016-2030)

12.5.5.  Market Revenue and Forecast, By End-user (2016-2030)

12.5.6.  Brazil

12.5.6.1.      Market Revenue and Forecast, By Phase (2016-2030)

12.5.6.2.      Market Revenue and Forecast, By Type (2016-2030)

12.5.6.3.      Market Revenue and Forecast, By Test (2016-2030)

12.5.6.4.      Market Revenue and Forecast, By Therapeutic Area (2016-2030)

12.5.7.  Market Revenue and Forecast, By End-user (2016-2030)

12.5.8.  Rest of LATAM

12.5.8.1.      Market Revenue and Forecast, By Phase (2016-2030)

12.5.8.2.      Market Revenue and Forecast, By Type (2016-2030)

12.5.8.3.      Market Revenue and Forecast, By Test (2016-2030)

12.5.8.4.      Market Revenue and Forecast, By Therapeutic Area (2016-2030)

12.5.8.5.      Market Revenue and Forecast, By End-user (2016-2030)

Chapter 13.  Company Profiles

13.1.              Covance, Inc.

13.1.1.  Company Overview

13.1.2.  Product Offerings

13.1.3.  Financial Performance

13.1.4.  Recent Initiatives

13.2.              IQVIA

13.2.1.  Company Overview

13.2.2.  Product Offerings

13.2.3.  Financial Performance

13.2.4.  Recent Initiatives

13.3.              Syneos Health

13.3.1.  Company Overview

13.3.2.  Product Offerings

13.3.3.  Financial Performance

13.3.4.  Recent Initiatives

13.4.              SGS SA

13.4.1.  Company Overview

13.4.2.  Product Offerings

13.4.3.  Financial Performance

13.4.4.  Recent Initiatives

13.5.              Toxikon

13.5.1.  Company Overview

13.5.2.  Product Offerings

13.5.3.  Financial Performance

13.5.4.  Recent Initiatives

13.6.              Intertek Group plc

13.6.1.  Company Overview

13.6.2.  Product Offerings

13.6.3.  Financial Performance

13.6.4.  Recent Initiatives

13.7.              Pace Analytical Services LLC

13.7.1.  Company Overview

13.7.2.  Product Offerings

13.7.3.  Financial Performance

13.7.4.  Recent Initiatives

13.8.              PPD, INC.

13.8.1.  Company Overview

13.8.2.  Product Offerings

13.8.3.  Financial Performance

13.8.4.  Recent Initiatives

13.9.              ICON plc

13.9.1.  Company Overview

13.9.2.  Product Offerings

13.9.3.  Financial Performance

13.9.4.  Recent Initiatives

13.10.           Charles River Laboratories International

13.10.1.               Company Overview

13.10.2.               Product Offerings

13.10.3.               Financial Performance

13.10.4.               Recent Initiatives

Chapter 14.  Research Methodology

14.1.              Primary Research

14.2.              Secondary Research

14.3.              Assumptions

Chapter 15.  Appendix

15.1.              About Us

Glossary of Terms